Advertisement
U.S. markets open in 3 hours 11 minutes
  • S&P Futures

    5,205.50
    -9.25 (-0.18%)
     
  • Dow Futures

    39,187.00
    -36.00 (-0.09%)
     
  • Nasdaq Futures

    18,183.75
    -47.75 (-0.26%)
     
  • Russell 2000 Futures

    2,045.20
    -4.60 (-0.22%)
     
  • Crude Oil

    82.60
    -0.12 (-0.15%)
     
  • Gold

    2,156.10
    -8.20 (-0.38%)
     
  • Silver

    25.09
    -0.17 (-0.69%)
     
  • EUR/USD

    1.0845
    -0.0032 (-0.29%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.64
    +0.31 (+2.16%)
     
  • GBP/USD

    1.2674
    -0.0054 (-0.43%)
     
  • USD/JPY

    150.5790
    +1.4810 (+0.99%)
     
  • Bitcoin USD

    63,346.57
    -4,432.20 (-6.54%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,721.25
    -1.30 (-0.02%)
     
  • Nikkei 225

    40,003.60
    +263.20 (+0.66%)
     

Europe approves Gilead's new hepatitis C pill

LONDON, Jan 17 (Reuters) - Gilead Sciences Inc's high-profile new hepatitis C drug Sovaldi has won final European approval, the company said on Friday, paving the way for its launch across the European Union.

The green light from the European Commission had been expected following a positive recommendation from the European Medicines Agency in November.

The once-a-day pill, also known as sofosbuvir, is the first approved to treat certain types of hepatitis C infection without the need for interferon, an injected drug that can cause severe flu-like symptoms.

Advertisement